TOP Study Design and Results

The TOP study represents the first randomized prospective phase III trial specifically examining patients with EGFR stage IV disease and concurrent TP53 mutations. This international, open-label, randomized controlled trial enrolled patients with untreated stage IV or recurrent EGFR-mutant NSCLC harboring exon 19 deletions or L858R mutations along with concurrent TP53 mutations.

Eligibility criteria included ECOG performance status 0 to 1 and stable central nervous system (CNS) metastases. Patients were randomized 1:1 to osimertinib plus chemotherapy versus osimertinib monotherapy, with stratification according to EGFR mutation type, brain metastases presence, and performance status.

Importantly, TP53 detection utilized tissue-based testing rather than circulating tumor DNA approaches used in other trials' post-hoc analyses, creating a more homogeneous patient population with systematic molecular characterization.

The results proved striking: median progression-free survival reached 34 months with combination therapy versus 15.6 months with osimertinib alone, more than doubling survival outcomes with a hazard ratio of 0.44. The absolute gain exceeded 18 months, surpassing the average benefit observed in FLAURA2 for the entire population.

Overall response rates also favored combination therapy at 82.9% versus 72%, whereas interim overall survival analysis showed a hazard ratio of 0.57, though these data remain immature requiring additional follow-up.

Dr. Olazagasti emphasizes the profound magnitude of benefit, noting such dramatic hazard ratios are uncommon in modern oncology trials. The data particularly supports community oncologists comfortable with osimertinib monotherapy by providing clear guidance for identifying patients requiring treatment intensification. These results represent definitive evidence supporting combination approaches for TP53-mutant patients rather than relying on clinical intuition alone.